Neuroscience is evolving at a rapid pace. The last two decades of biotech have been dominated by oncology and infectious diseases, but artificial intelligence and in vitro tech are revamping the pharma landscape for neuropsychiatric disorders. Patients with autism, traumatic brain injury, and neurodegeneration are seeing true innovation for the first time.

We are taking a "contrarian" approach to innovation by focusing on new theoretical frameworks - neuromodulation and neuroinflammation.

Our due diligence is supported by a network of institutional advisors from top biotech & psychedelic firms.

Deal flow is generated through Hector Ventures' investment network - HV is invested in 5 funds with a collective total of more than $250 AUM. We combine their technical/financial due diligence with our neuroscience-specific expertise to select top opportunities.